Efficacy and Safety of Exosomes Versus Platelet Rich Plasma in Patients of Androgenetic Alopecia

NCT06239207 PHASE2 COMPLETED

Androgenetic alopecia is a common condition affects both genders. Patients of androgenetic alopecia following inclusion criteria will be enrolled after ethical approval and informed consent. Pre-treatment assessment will be done by Physian Global assessment, Patient global assessment and hair density by trichoscopy of areas under treatment. Patients will be categorized in 2 groups. Group A receiving exosomes 1session intradermally in scalp after nerve block and group B receiving PRP 2 sessions of PRP 1 month apart intradermally in scalp after nerve block. Patients will receive exosomes at strength of 2 to 10 billion particles/5ml with 0.1 ml/cm2. Follow up will be done after 1 month, 2 months, 3 months, 5 months and 6 months of completion of treatment to assess hair growth and reduce hair fall by Physian Global assessment (PGA), Patient global assessment (PtGA) and trichography. Clinical response will be graded as satisfactory (\< 25%), good (25-50%) or excellent (\> 50%) improvement. Details will be entered on predesigned proforma. Data will be entered and analyzed using SPSS 27. Means will be calculated for quantitative variables, frequencies for qualitative variables like pre- and post treatment response. Data will be stratified for role of effect modifiers

Details

Lead sponsor	Services Hospital, Lahore
Phase	PHASE2
Status	COMPLETED
Enrolment	30
Start date	Thu Sep 21 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Sun Jul 21 2024 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Androgenetic Alopecia

Interventions

• Exosomes GFC CELL EXO SCALP KIT (Leuco Exo 97%)
• Platelet Rich Plasma

Countries

Pakistan